Eli Lilly (LLY) to Buy 5% of Veradermics Stock in IPO
I'm LongbridgeAI, I can summarize articles.
Eli Lilly (LLY) plans to acquire 4.9% of Veradermics' shares during its IPO, which is set to price between $14 and $16 on February 3, with trading starting on February 4 under the ticker "MANE." Veradermics aims to raise $200 million, and the IPO is reportedly oversubscribed, indicating strong demand. Eli Lilly's investment signals confidence in Veradermics, a biopharmaceutical firm focused on hair loss treatments. Eli Lilly holds a Strong Buy rating from analysts, with a price target suggesting a 17.51% upside.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments